Scribe Therapeutics Inc. (the “Company”) is a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention. The Company was incorporated in the state of Delaware in June 2017.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Stage not disclosed · ActiveModality: in vivo CRISPR genetic medicine
Target PCSK9
Indications
Atherosclerotic cardiovascular disease (ASCVD)(Stage not disclosed)
Status note Lead product candidate for ASCVD. Filing excerpts do not state its phase or target gene; company describes itself as clinical-stage. Platform agreements (not asset-specific in excerpts): UC Regents exclusive license (CRISPR IP); Acuitas LNP development/option + non-exclusive license.
STX-1200
Preclinical · ActiveModality: in vivo CRISPR genetic medicine
Target LPA
Partnerships CIRM: ~$12.7M preclinical development award (Apr 2026-Mar 2029 project period).
Indications
ASCVD(Preclinical)
Status note Developmental program; preclinical per CIRM funding for preclinical development.
STX-1400
Preclinical · ActiveModality: in vivo CRISPR genetic medicine
Target APOC3
Partnerships CIRM: ~$13.0M preclinical development award (Apr 2026-Sep 2029 project period).
Indications
ASCVD(Preclinical)
Status note Developmental program; preclinical per CIRM funding for preclinical development.
Per-asset detail extracted from the 10-Q filed 2026-09-02. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.